JunHe Assists Pharmaron (Beijing) New Drug Technology Co., Ltd. in its Listing on m88 casino review Main Board of m88 casino review SEHX

Pharmaron (Beijing) New Drug Technology Co., Ltd. (‘Pharmaron’, with Stock Code 03759.HK) listed on m88 casino review main board of m88 casino review SEHX on November 28, 2019. It issued 116,536,100 shares globally at an issue price of HKD 39.50, and HKD 4,603,000,000 was raised. m88 casino review net issuance value was expected to be HKD 4,344,000,000. In Hong Kong, m88 casino review number of shares subscribed was 114.23 times more than m88 casino review number of shares issued and market investors showed great interest in m88 casino review subscription. m88 casino review issuance and m88 casino review listing on m88 casino review H-share market represented Pharmaron’s successful landing on both m88 casino review A-share market and m88 casino review H-share market in 2019. Pharmaron m88 casino reviewrefore became m88 casino review second CRO company to have m88 casino review “A+H” ownership structure. m88 casino review project was consummated in a short timeframe of six months.

Pharmaron was founded in 2004 and currently is m88 casino review second largest pharmaceutical R&D platform in China. It is one of m88 casino review top three drug discovery service providers in m88 casino review world and its customers include some of m88 casino review top 20 multinational pharmaceutical companies in m88 casino review world (such as AstraZeneca, Merck Sharp & Dohme, Johnson & Johnson and Bayer).

In m88 casino review past, Pharmaron adopted a red-chip structure. Accordingly, it not only owned businesses and assets in China, but it also had businesses and assets in Hong Kong, m88 casino review United States and m88 casino review United Kingdom. Pharmaron has established more than ten R&D service centers around m88 casino review world. JunHe’s team fully cooperated with om88 casino reviewr intermediaries to assist m88 casino reviewir client in dealing with complicated and volatile markets. JunHe’s timely assistance provided Pharmaron with support throughout each stage and our efficient and excellent work won m88 casino review recognition of m88 casino review client.

JunHe was m88 casino review Chinese legal counsel of Goldman Sachs (Asia) L.L.C., CITIC CLSA Capital Markets Limited and Orient Capital (Hong Kong) Limited (each, a co-sponsor of m88 casino review project) in m88 casino review project.

PartnerM88 Game ,合伙人,专业领域,资本市场,私募股权创业投资led m88 casino review project and Partnerm88 casino appwas m88 casino review acting lawyer for m88 casino review project.